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Abstract
Background: Delta neutrophil index (DNI), representing an elevated fraction of circulating immature granulocytes
in acute infection, has been reported as a useful marker for predicting mortality in patients with sepsis. The aim of
this study was to evaluate the prognostic value of DNI in predicting mortality in septic acute kidney injury (S-AKI)
patients treated with continuous renal replacement therapy (CRRT).
Method: This is a retrospective analysis of consecutively CRRT treated patients. We enrolled 286 S-AKI patients who
underwent CRRT and divided them into three groups based on the tertiles of DNI at CRRT initiation (high, DNI > 12.
0%; intermediate, 3.6–12.0%; low, < 3.6%). Patient survival was estimated with the Kaplan-Meier method and Cox
proportional hazards models to determine the effect of DNI on the mortality of S-AKI patients.
Results: Patients in the highest tertile of DNI showed higher Acute Physiology and Chronic Health Evaluation II
score (highest tertile, 27.9 ± 7.0; lowest tertile, 24.6 ± 8.3; P = 0.003) and Sequential Organ Failure Assessment score
(highest tertile, 14.1 ± 3.0; lowest tertile, 12.1 ± 4.0; P = 0.001). The 28-day mortality rate was significantly higher in
the highest tertile group than in the lower two tertile groups (P < 0.001). In the multiple Cox proportional hazard
model, DNI was an independent predictor for mortality after adjusting multiple confounding factors (hazard ratio,
1.010; 95% confidence interval, 1.001–1.019; P = 0.036).
Conclusion: This study suggests that DNI is independently associated with mortality of S-AKI patients on CRRT.
Keywords: Delta neutrophil index, Septic acute kidney injury, Continuous renal replacement therapy, Mortality
Background
Acute kidney injury (AKI) is a common and serious
complication in critically ill patients [1, 2]. Septic AKI
(S-AKI) accounts for close to 50% of all cases of AKI in
the intensive care unit (ICU), and affects between 15
and 20% of patients in the ICU [3]. Continuous renal re-
placement therapy (CRRT) is an established treatment
modality in critically ill patients with AKI in the ICU
[4]. CRRT has several advantages in regard with the
hemodynamic stability in patients with sepsis compared
to intermittent renal replacement therapy including trad-
itional dialysis and ultrafiltration therapy [5, 6].
In spite of potential advantages of CRRT in the manage-
ment of S-AKI, the mortality rate in this patient group re-
mains extremely high [7, 8]. To identify the predictors of
mortality rate in S-AKI patients on CRRT treatment, sev-
eral observational studies have been described [9, 10]. Pre-
vious studies focused on not only variable clinical factors
but also sepsis or systemic inflammatory response syn-
drome (SIRS) related inflammatory mediators. Circulating
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pro- and anti-inflammatory cytokines, such as tumor ne-
crosis factor (TNF)-α, interleukin (IL)-6, and IL-8, play an
important role in the pathogenesis and progression of S-
AKI and have been introduced as potential biomarkers of
S-AKI. C-reactive protein (CRP) and procalcitonin were
used to help predict mortality risk in patients with sepsis
[11–13]. However, these biomarkers have not been found
to be easily applicable due to limitations of timeliness and
cost-effectiveness in critically ill S-AKI patients [12, 14].
Delta neutrophil index (DNI), calculated by subtracting
the fraction of mature polymorphonuclear leukocytes from
myeloperoxidase (MPO) reactive cells, represents propor-
tion of circulating immature granulocytes (IGs). DNI is pro-
vided by an automatic hematologic analyzer ADVIA2120
(Siemens Healthcare Diagnostics, Forchheim, Germany)
using MPO and nuclear lobularity channels [15]. A previ-
ous study demonstrated that, compared with white blood
cells (WBCs) or CRP levels, DNI is a more useful marker
for predicting mortality in patients with sepsis [16]. DNI
has several advantages: it is simple, automatically reported,
and rapidly recognized. However, little is known about the
prognostic role of DNI in S-AKI patients, especially those
treated with CRRT. Therefore, in this study, we explored
whether high DNI is associated with high mortality rates in
S-AKI patients receiving CRRT treatment at a single ICU
center in Republic of Korea.
Methods
Study subjects
All data from patients were retrieved from CRRT Data-
base at Severance Hospital, Yonsei University Health Sys-
tem (YUHS) in Seoul, Republic of Korea. YUHS operates
a specialized CRRT team (SCT), which includes physi-
cians and nurses who are especially trained and educated
in performing CRRT. Related details have been previously
described [8]. Through a retrospective review of the con-
secutively registered CRRT Database, 628 patients who
started CRRT from August 2011 to September 2013 were
considered eligible for the present study. We excluded 121
patients who were younger than 18 years and/or the pres-
ence of a do-not-resuscitate (DNR) order. Because DNI
values do not adequately work in immunocompromised
individuals [17], the subject seems like has the compo-
nents of immune suppression such as individuals those
who have previously experienced chronic dialysis, or diag-
nosed with advanced stage IV malignancies, liver cirrhosis
(Child-Pugh C), or higher than 40 points with Acute
Physiology and Chronic Health Evaluation (APACHE) II
score at enrollment were also excluded. The survival ana-
lysis according to the DNI groups was only performed
with S-AKI populations (n = 286, Fig. 1).
To define the sepsis, we followed the consensus con-
ference criteria from the American College of Chest
Physicians/Society of Critical Care Medicine [18]. The
individual those who had clinical findings supposed in-
fection and simultaneously had 2 consecutive factors
agree with SIRS, they diagnosed as the presence of sep-
sis. In SIRS, at least 2 of the following criteria were re-
quired: 1) core temperature > 38 °C or < 36 °C, 2) heart
rate > 90 beats per minute, 3) respiratory rate > 20
breaths per minute, 4) arterial partial pressure of CO2 <
32 mmHg, 5) peripheral leukocyte count > 12,000/mm3
or < 4,000/mm3 [19]. To define SIRS, we used the results
of vital signs and biochemical tests that were measured
just before beginning of CRRT.
We included AKI patients with injury or failure
stage of Risk, Injury, Failure, Loss of kidney function,
and End-stage kidney disease (RIFLE) criteria at the
time of CRRT initiation [20]. S-AKI was defined as
SIRS combined with an infectious episode and renal
dysfunction.
Data collection
Depending on the protocol performed by SCT, all pa-
tients receiving CRRT were recorded with demographic
and biochemical data including DNI at the beginning of
CRRT, and these information were collected retrospect-
ively for present analyses. Actually, blood samples com-
prising resource for DNI calculation was retrieved at the
time immediately before the initiation of CRRT. Data of
complete blood cell (CBC) counts were collected from an
automated hematology analyzer (ADVIA 2120). DNI was
calculated using the following formula: DNI (%) = (the
leukocyte subfraction assayed in the MPO channel by cy-
tochemical reaction) − (leukocyte subfraction counted in
the nuclear lobularity channel by reflected light beam)
[15]. Mean arterial pressure (MAP) was defined as dia-
stolic pressure plus a third of the pulse pressure, and re-
corded at the time of initiating CRRT. For the assessment
of disease severity, Sequential Organ Failure Assessment
(SOFA) score, APACHE II score, and Charlson Comorbid-
ity Index (CCI) were evaluated at the start of CRRT treat-
ment. Comorbidities were defined by diagnosis codes
based on the International Statistical Classification of Dis-
eases and Related Health Problems, 10th revision. Subjects
who were taking antihypertensive or antidiabetic medica-
tions were also considered hypertensive or having dia-
betes, respectively. The following biochemical laboratory
test result data were collected: hemoglobin, WBCs, plate-
let, blood urea nitrogen, serum creatinine, total choles-
terol, serum albumin, high sensitivity CRP (hs-CRP), total
bilirubin, prothrombin time (PT), and activated partial
thromboplastin time (aPTT). The estimated glomerular
filtration rate (eGFR) was calculated by using the chronic
kidney disease epidemiology collaboration equation [21],
and hs-CRP levels were determined by a latex-enhanced
immunonephelometric method using a BNII analyzer
(Dade Behring, Newark, DE, USA).
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ICU setting and CRRT protocol
The investigation site was a self-contained, 99-bed med-
ical and surgical ICU in a 2076-bed teaching hospital in
Seoul, Republic of Korea, equipped with 15 CRRT ma-
chines. CRRT initiation criteria include medically in-
tractable and persistent electrolyte imbalance and/or
metabolic acidosis, as well as decreased urine volume
with overhydrated status and/or progressive azotemia.
Hemodynamic instability was also considered an import-
ant factor in decision-making. However, the final deci-
sion to start CRRT was based on comprehensive
judgment of various indications. Specifically, decisions
to determine CRRT settings, which included target re-
moval, blood flow, dialysate and replacement fluid rates,
and the use of anticoagulant, were finalized by the
nephrologist after close consultations and discussions be-
tween nephrologists, physicians, and ICU practitioners.
Vascular accesses for CRRT have been selected among
via the femoral, internal, or subclavian veins accord-
ing to their availability and combined comorbidities.
In most patients, continuous venovenous hemodiafil-
tration (CVVHDF) was performed using the PRISMA
platform (Gambro, Hechingen, Germany). CRRT was
initiated with a blood flow rate of 100 mL/min, which
was gradually increased to 150 mL/min. The ultrafiltration
dose was targeted to 40 mL/kg/h, and Hemosol (Gambro)
was replaced using a predilution method. In addition,
CRRT circuits were exchanged regularly every 48 h or
when the blood pump was stopped. The patients were
weighted every morning using an in-bed scale, and the
ultratfiltration dose was adjusted [22].
Statistical analysis
Statistical analysis was performed using IBM SPSS soft-
ware for Windows version 23.0 (IBM Corporation,
Armonk, NY, USA). Continuous variables were presented
as means as standard deviation, and categorical variables
as numbers and percentages. Patients were divided into
three groups based on tertiles of DNI values at CRRT
initiation: high, intermediate, and low DNI groups. The
Shapiro-Wilk test was used to analyze the normality of
the distribution of parameters. Baseline characteristics
according the trichotomized DNI groups were compared
using the one-way analysis of variance (ANOVA) for
continuous variables and chi-square test for categorical
variables. Nonparametric variables were expressed as me-
dian and interquartile range and compared using the
Kruskal-Wallis test. To compare differences of continuous
parameters between survivors and non-survivors, Stu-
dent’s t-test or the Mann-Whitney U-test were used for
parametric or non-parametric variables, respectively.
Pearson correlation coefficients were used to assess the
relationship between DNI and variable selected clinical
parameters. In the present study, we evaluated 28-day all-
cause mortality as an end point. Survival curves were gen-
erated by the Kaplan-Meier method, and between-group
survival was compared by the log-rank test. We con-
ducted receiver operating characteristic (ROC) analysis to
compare the predictive accuracy of DNI and SOFA scores,
and area under the curve (AUC) was calculated. In
addition, we graded by DNI on a scale of 1–3 (DNI <
3.6%, 1; 3.6% ≤DNI ≤ 12.0%, 2; DNI > 12.0%, 3) and added
to the baseline SOFA score. The independent prognostic
values of clinical parameters for the study outcome were
analyzed by multiple Cox regression analysis. Hazard ra-
tios (HRs) and 95% confidence intervals (CIs) were calcu-
lated with the use of the estimated regression coefficients
and standard errors in the Cox regression analysis. The
independent association of DNI levels for the 28-day all-
cause mortality was confirmed by multiple logistic regres-
sion analysis. All probabilities were two-tailed and the
level of significance was set at 0.05.
Fig. 1 Flow diagram of the study. Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; DNI, delta neutrophil index
Han et al. BMC Nephrology  (2017) 18:94 Page 3 of 10
Results
Population characteristics
The demographic and biochemical characteristics of the
study population with S-AKI are shown in Table 1. At
the time of ICU admission, 129 (45.1%), 82 (28.7%), and
75 (26.2%) patients were classified as RIFLE-R, −I, and
-F, respectively. Meanwhile, 177 (61.9%) patients were
classified as RIFLE-I, and the remaining 109 (38.1%) pa-
tients were classified as RIFLE-F at the time of CRRT.
DNI values ranged from 0 to 73.40%, with a median of
6.10%. When the patients were divided into three groups
based on the tertiles of DNI level at CRRT initiation
(high, DNI > 12.0%; intermediate, 3.6–12.0%; low, < 3.6%),
patients with the highest tertile of DNI had higher APA-
CHE II scores (27.9 ± 7.0 vs. 24.6 ± 8.3, P = 0.003) and
SOFA scores (14.1 ± 3.0 vs. 12.1 ± 4.0, P = 0.001)
compared to the lowest tertile group. Patients with the
highest tertile of DNI had lower MAP, WBCs, platelet,
and total cholesterol levels. In addition, they had more
prolonged PT and aPTT. However, there were no signifi-
cant differences in age, gender, CCI score, hemoglobin,
eGFR, and hs-CRP among three groups.
When the study population divided into two groups
according to their mortality events, non-survivor group
showed significantly higher APACHE II (28.1 ± 7.3 vs.
24.0 ± 7.5, P < 0.001) and SOFA (14.2 ± 3.1 vs. 10.8 ± 3.7,
P < 0.001) score, higher DNI [8.35 (3.23–24.73) vs. 3.95
(2.35–9.10) %, P < 0.001], PT (1.7 ± 0.8 vs. 1.5 ± 0.6 INR,
P = 0.007), and aPTT (53.1 ± 31.9 vs. 40.4 ± 14.6 s, P <
0.001) levels compared with survivor group, while MAP
(73.1 ± 12.8 vs. 81.7 ± 13.9 mmHg, P < 0.001), history of
hypertension [65 (33.9%) vs. 46 (48.9%), P = 0.014] and
Table 1 Baseline characteristics of patients according to delta neutrophil index
Variables Total (n = 286) 1st tertile
(n = 94, < 3.6%)
2nd tertile
(n = 96, 3.6–12.0%)
3rd tertile
(n = 96, > 12.0%)
P value
Age (year) 61.0 ± 14.7 60.6 ± 15.5 62.2 ± 14.8 60.2 ± 13.8 0.626
Male (%) 180 (63.2) 58 (62.4) 57 (59.4) 65 (67.7) 0.480
MAP (mmHg) 75.9 ± 13.7 78.9 ± 15.7 75.7 ± 12.1 73.3 ± 12.7 0.016
APACHE II score 26.8 ± 7.6 24.6 ± 8.3 28.0 ± 7.2 27.9 ± 7.0 0.003
SOFA score 13.1 ± 3.7 12.1 ± 4.0 13.1 ± 3.8 14.1 ± 3.0 0.001
Charlson comorbidity score 13.1 ± 2.1 13.2 ± 2.2 13.0 ± 2.2 12.9 ± 1.8 0.611
RIFLE criteria (%)a
Risk 129 (45.1) 42 (44.7) 45 (46.9) 42 (43.8) 0.666
Injury 82 (28.7) 25 (26.6) 31 (32.3) 26 (27.1)
Failure 75 (26.2) 27 (28.7) 20 (20.8) 28 (29.2)
Comorbid diseases (%)
Hypertension 111 (38.8) 40 (42.6) 43 (44.8) 28 (29.2) 0.056
Diabetes mellitus 98 (34.3) 42 (44.7) 32 (33.3) 24 (25.0) 0.016
Biochemical data
DNI (%) 6.10 (2.73–19.78) 1.35 (0–2.71) 6.00 (4.40–8.40) 27.9 (19.18–43.60) <0.001b
Hemoglobin (g/dL) 9.6 ± 5.3 9.3 ± 2.2 9.4 ± 2.1 10.3 ± 8.6 0.349
WBC (103/mm3) 11.6 (5.7–18.1) 13.6 (7.0–17.4) 13.9 (9.5–20.6) 7.5 (3.3–17.5) 0.002b
Platelet (103/ mm3) 86 (51–163) 112 (62–207) 100 (61–185) 57 (41–94) <0.001b
eGFR (mL/min/1.73 m2) 30.9 ± 17.0 27.9 ± 16.0 32.3 ± 17.2 32.5 ± 17.6 0.114
Cholesterol (mg/dL) 93.2 ± 47.8 104.7 ± 51.4 94.3 ± 44.8 81.4 ± 44.7 0.008
Albumin (g/dL) 2.7 ± 0.6 2.8 ± 0.6 2.7 ± 0.7 2.6 ± 0.6 0.088
hs-CRP (mg/L) 104.6 (34.3–199.8) 71.4 (19.7–160.1) 114.5 (44.0–196.8) 128.3 (35.6–279.9) 0.126b
Total bilirubin (mg/dL) 1.6 (0.7–3.6) 1.6 (0.7–4.7) 1.4 (0.6–3.6) 1.9 (0.7–3.4) 0.523b
PT (INR) 1.6 ± 0.7 1.6 ± 0.6 1.5 ± 0.6 1.8 ± 0.8 0.003
aPTT (sec) 48.9 ± 28.0 42.0 ± 16.2 44.1 ± 22.7 59.8 ± 36.9 <0.001
Abbreviations: MAP mean arterial pressure, APACHE Acute Physiology and Chronic Health Evaluation, SOFA Sequential Organ Failure Assessment, DM diabetes
mellitus, DNI delta neutrophil index, WBC white blood cells, Cr creatinine, eGFR estimated glomerular filtration rate, hs-CRP high sensitivity C-reactive protein, PT
prothrombin time, aPTT activated partial thromboplastin time, ICU intensive care unit
aAt ICU hospitalization; At the time of CRRT, 177 (61.9%) patients were classified as RIFLE-I, and the remaining 109 (38.1%) patients were classified as RIFEL-F;
bKruskal-Wallis test
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diabetes [58 (30.2%) vs. 40 (42.6%), P = 0.039], WBCs
[10.6 (4.0–17.5) vs. 13.9 (8.9–20.3) 103/mm3, P = 0.009],
platelet counts [80 (44–129) vs. 114 (57–204) 103/mm3,
P = 0.002], and serum albumin concentrations (2.6 ± 0.6
vs. 2.8 ± 0.7 g/dL, P = 0.013) were significantly lower in
non-survivor group (Table 2).
Associations between DNI values and other parameters
There were significant negative correlations between
baseline DNI values and MAP (r = −0.159, P = 0.007),
platelets (r = −0.219, P < 0.001), and albumin (r = −0.150,
P = 0.012). In contrast, there were positive correlations
between baseline DNI values and APACHE II score
(r = 0.119, P = 0.045), SOFA score (r = 0.166, P = 0.005),
PT (r = 0.160, P = 0.008), and aPTT (r = 0.268, P < 0.001).
There was no correlation in DNI levels with WBC, eGFR,
and hs-CRP (Table 3).
Risk analysis for all-cause mortality
During the study period, 192 (67.1%) patients died.
Twenty-eight-day mortality rate was significantly higher in
the highest DNI group compared with intermediate and
lowest DNI groups (80.2 vs. 64.6 vs. 56.4%, P < 0.001,
Fig. 2). In Cox regression analysis in which DNI levels
were treated as a continuous variable, DNI level was
significantly associated with 28-day mortality (per 1% in-
crease of DNI; HR 1.014; 95% CI, 1.007–1.022; P < 0.001)
(Table 4, Model 1). After adjustment for age, gender,
MAP, and SOFA score were included in a multivariate
model, DNI remained an independent predictor of 28-day
mortality (HR 1.011; 95% CI, 1.003–1.019; P = 0.010)
(Table 4, Model 3). In addition, the significance was
remained even more adjustment for platelet, albu-
min, PT, and aPTT (HR 1.010; 95% CI, 1.001–1.019;
P = 0.036) (Table 4, Model 4). Meanwhile, we did not
find any significant differences according to DNI
Table 2 Baseline characteristics of patients according to the 28-day mortality event
Variables Survivor
(n = 94, 32.9%)
Non-survivor
(n = 192, 67.1%)
P value
Age (year) 59.6 ± 14.9 61.7 ± 14.6 0.257
Male (%) 61 (65.6) 119 (62.0) 0.553
MAP (mmHg) 81.7 ± 13.9 73.1 ± 12.8 <0.001
APACHE II score 24.0 ± 7.5 28.1 ± 7.3 <0.001
SOFA score 10.8 ± 3.7 14.2 ± 3.1 <0.001
Charlson comorbidity score 12.9 ± 2.3 13.1 ± 2.0 0.347
RIFLE criteria (%)a
Risk 48 (51.1) 81 (42.2) 0.345
Injury 23 (24.5) 59 (30.7)
Failure 23 (24.5) 52 (27.1)
Comorbid diseases (%)
Hypertension 46 (48.9) 65 (33.9) 0.014
Diabetes mellitus 40 (42.6) 58 (30.2) 0.039
Biochemical data
DNI (%) 3.95 (2.35–9.10) 8.35 (3.23–24.73) <0.001b
Hemoglobin (g/dL) 10.5 ± 8.7 9.2 ± 2.2 0.063
WBC (103/mm3) 13.9 (8.9–20.3) 10.6 (4.0–17.5) 0.009b
Platelet (103/ mm3) 114 (57–204) 80 (44–129) 0.002b
eGFR (mL/min/1.73 m2) 76.7 ± 32.5 80.4 ± 29.2 0.404
Cholesterol (mg/dL) 98.1 ± 50.5 90.9 ± 46.5 0.271
Albumin (g/dL) 2.8 ± 0.7 2.6 ± 0.6 0.013
hs-CRP (mg/L) 106.0 (49.7–205.5) 102.6 (26.7–198.0) 0.581b
Total bilirubin (mg/dL) 1.4 (0.6–3.0) 1.9 (0.7–4.5) 0.101b
PT (INR) 1.5 ± 0.6 1.7 ± 0.8 0.007
aPTT (sec) 40.4 ± 14.6 53.1 ± 31.9 <0.001
Abbreviations: MAP mean arterial pressure, APACHE Acute Physiology and Chronic Health Evaluation, SOFA Sequential Organ Failure Assessment, DM diabetes
mellitus, DNI delta neutrophil index, WBC white blood cells, Cr creatinine, eGFR estimated glomerular filtration rate, hs-CRP high sensitivity C-reactive protein, PT
prothrombin time, aPTT activated partial thromboplastin time, ICU intensive care unit
aAt ICU hospitalization; bMann-Whitney U-test
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levels in patients with non-S-AKI (data not shown,
Model 4, P = 0.638).
The relationship between the 28-day mortality rates
and DNI values was confirmed by multiple logistic re-
gression analyses with adjustments for multiple con-
founding factors (Table 4). In the fully adjusted model,
increased DNI levels were still independently associated
with the risk of 28-day mortality event in S-AKI patients
[DNI, 1% increase, odds ratio (OR), 95% confidence
interval (CI) = 1.024 (1.002–1.046), P = 0.031]. The ROC
curves using variables (DNI value, hs-CRP, and WBC
counts) are plotted in Fig. 3. The AUCs of DNI value
and hs-CRP for 28-day all-cause mortality were 0.635
and 0.526, respectively (P < 0.001, Fig. 3).
Discussion
This study demonstrated that DNI value is closely re-
lated to severity of disease in patients with S-AKI. In
addition, baseline DNI level is independently associated
with mortality in S-AKI patients treated with CRRT,
even after adjusting for other established prognostic var-
iables such as SOFA score.
DNI is the difference between the leukocyte differen-
tial assayed in the MPO channel and that measured in
the nuclear lobularity channel, and was initially designed
as a reliable and reproducible method to reflect IGs in
circulating blood. The shift to the left of neutrophils,
which reflects elevated IGs, has been characterized in
sepsis and SIRS. Leukocyte count could be variable ac-
cording to severity of sepsis in patients in the ICU.
WBC count can increase in response to bacterial infec-
tion. Meanwhile, sepsis-associated leukopenia has been
explained by impaired bone marrow production and per-
ipheral overconsumption and/or destruction in response
to disseminated intravascular coagulation (DIC). Several
studies reported that DNI was closely related to sepsis
severity [23], detection rate of blood cultures [24], DIC
scores [15], and mortality in patients with suspected sep-
sis [16]. Moreover, another study showed that DNI may
serve as a more useful diagnostic and prognostic marker
than lactate for early diagnosis of disease severity in pa-
tients with septic shock [25]. More recently, leaving the
usefulness of DNI on the field of critical medicine aside,
DNI showed the association with several inflammatory
status which could be overlooked by clinicians such as
acute appendicitis, low-grade community-acquired
pneumonia, or pyelonephritis in transplanted subjects
[26–28]. There were no significant differences in WBC
counts or neutrophil proportion among the groups
Table 3 Correlation between baseline delta neutrophil index
and selected clinical parameters
Variables Delta neutrophil index (%)
γ P value
Mean arterial pressure (mmHg) −0.159 0.007
APACHE II score 0.119 0.045
SOFA score 0.166 0.005
WBC (103/mm3) 0.030 0.609
Platelet (103/mm3) −0.219 <0.001
eGFR (mL/min/1.73 m2) 0.022 0.716
Albumin (g/dL) −0.150 0.012
hs-CRP (mg/L) 0.135 0.073
PT (INR) 0.160 0.008
aPTT (sec) 0.268 <0.001
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; SOFA,
Sequential Organ Failure Assessment; WBC, white blood cells; eGFR, estimated
glomerular filtration rate; hs-CRP, high sensitivity C-reactive protein; PT, prothrombin
time; aPTT, activated partial thromboplastin time
Fig. 2 Kaplan-Meier plots for 28-day mortality-free survival rates. The comparison were conducted with trichotomized DNI groups. Abbreviations:
DNI, delta neutrophil index
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categorized using DNI values. In addition, WBC counts
alone did not predict patient outcomes. However, there
were significant relationships between DNI and DIC-
related parameters, including platelet count, PT, and
aPTT. These findings added to the evidence that base-
line DNI is a significant determinant of mortality in AKI
patients requiring CRRT. In addition, DNI is routinely
performed and automatically calculated without add-
itional costs. DNI values can be rapidly recognized in
the CBC report. Taken together, we surmised that DNI
could be an early and potent prognostic indicator in pa-
tients with S-AKI.
Although DNI as a prognostic marker for sepsis might
be comparable to other pro-inflammatory cytokines such
as CRP and procalcitonin, DNI can change in conditions
of ineffective leukocyte production. Since the production
of IGs and DNI values could be suppressed in immuno-
compromised patients, DNI value alone could not dis-
criminate between bacteremia and non-bacteremia in
these patients. In addition, the production of IGs may be
altered in neonates, pregnant women, and patients with
other hematologic diseases or bone marrow alterations.
Under these conditions, DNI should be interpreted with
caution, and other biomarkers, such as CRP and procal-
citonin, might be included to assess the severity of SIRS
or sepsis.
Even though the present study measured IGs using the
ADVIA automatic analyzer, several other hematology
analyzers can obtain IG counts. The Cell-Dyn series
analyzer counts the IG fraction using a 4-dimensional
optical scanner and multi-parameter flow cytometry,
and the Sysmex analyzer also enumerates IG counts
using the difference of fluorescence between mature and
immature granulocytes, similar to the ADVIA analyzer.
Further comparative analyses among these techniques
might be conducted to validate the clinical usefulness in
sepsis patients including S-AKI patients.
Predictive scoring systems have been developed to
measure the severity of disease and the prognosis of pa-
tients with sepsis in the ICU [29, 30]. However, these
Table 4 Association of delta neutrophil index for 28-day all-cause mortality in patients underwent CRRT
Per 1% delta neutrophil index increase
Cox proportional hazard regression analyses Logistic regression analyses
Hazard ratio 95% CI P value Odds ratio 95% CI P value
Model 1 1.014 1.007–1.022 <0.001 1.034 1.013–1.055 0.001
Model 2 1.012 1.004–1.020 0.003 1.028 1.007–1.050 0.008
Model 3 1.011 1.003–1.019 0.010 1.024 1.003–1.046 0.027
Model 4 1.010 1.001–1.019 0.036 1.024 1.002–1.046 0.031
Model 1, crude model
Model 2, adjusted for age, gender, and mean arterial pressure
Model 3, Model 2 + SOFA score
Model 4, Model 3 + platelet, albumin, PT, and aPTT
Abbreviations: CRRT continuous renal replacement therapy, CI confidence interval, SOFA Sequential Organ Failure Assessment, PT prothrombin time, aPTT activated
partial thromboplastin time
Fig. 3 Receiver operating characteristics curve for the prediction of mortality event by DNI index. Abbreviations: DNI, delta neutrophil index; WBC,
white blood cell; CRP, C-reactive protein; AUC, area under the curve
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scoring systems have important limitations, such as in-
accuracy according to the type of disease [31–33], lead
time bias [34], and need for updating [35]. The accuracy
of prediction of mortality with severity scoring indices
alone is relatively poor. Therefore, other factors such as
serologic makers related to sepsis must be considered
together to predict the outcome in severe sepsis. A re-
cent study demonstrated that pro-inflammatory media-
tors such as TNF-α, IL-1ß, and IL-6 are important
clinical prognostic markers in patients with systemic
sepsis. There is a strong correlation between serum con-
centration of pro-inflammatory mediators and mortality
in septic patients [36]. In spite of this advantage, most of
these mediators are not established for clinical decision-
making due to their short half-life. In addition, the same
goal could be achieved more easily and cheaply by the
estimation of blood lactate level.
AKI has long been considered primarily as a hemo-
dynamic condition characterized by a reduction of renal
blood flow, induced by either cardiogenic or septic shock
[37]. However, Bellomo et al. produced new and interesting
data in animal models of S-AKI that undermined existing
concepts. They observed that medullary and cortical renal
blood flow were both maintained and even increased in
septic shock, underscoring that S-AKI was a totally differ-
ent physiological phenomenon than non-S-AKI [38]. In-
flammation is now believed to play a major role in the
pathophysiology of S-AKI [39]. In fact, it is known that
TNF-α can induce AKI [40], and Benes et al. found an early
increase in TNF-α in animals developing S-AKI [41]. In
addition, recent work highlighted the fact that inflamma-
tory apoptosis could play a more important role in sepsis
and septic shock than pure necrosis [42]. Interestingly,
Simmons et al. suggested that an increase in plasma pro-
inflammatory cytokine levels could predict mortality in pa-
tients with AKI. However, unlike other sepsis studies which
showed that pro-inflammatory cytokines like IL-1ß and
TNF-α could predict mortality, this study did not confirm
such a relationship. Instead, IL-6 and IL-8, which were
often considered secondary in the inflammatory cascades
involving IL-1ß or TNF-α, were proven to be significant
predictors of mortality. The authors suggested that renal
failure may in and of itself confer an altered cytokine profile
even in the context of critical illness. Another potential
explanation for this discrepancy may be the timing of
cytokine determination in the overall course of illness
[43]. Therefore, the extent to which inflammatory me-
diators affect the prognosis in patients with S-AKI re-
mains uncertain.
This study has several limitations. First, we did not
evaluate follow-up data for DNI levels and thus could
not account for possible variation over time. Since DNI
levels can change according to the response to optimal
treatment such as antibiotics, repeated measurement of
DNI can serve as a helpful predictor of prognosis in pa-
tients with sepsis or SIRS. Further study to clarify the re-
lationship of changes in DNI levels over time with
prognosis might be valuable. Second, there was no inves-
tigation of pro-inflammatory cytokines related to sepsis
in patients with S-AKI. Pro-inflammatory cytokines such
as TNF-α, IL-1ß, and IL-6 play a more important role in
the pathogenesis of sepsis and septic shock. In addition,
there is a strong correlation between serum concentration
of pro-inflammatory mediators and mortality in septic pa-
tients. The investigation of pro-inflammatory cytokines
compared with DNI might be helpful in predicting out-
comes in patients with S-AKI in the future. Third, DNI
values have limitations for assessing bacteremia in im-
munocompromised individuals, thus there might be inad-
equate estimation in patients with severe immune
suppression [17]. To mitigate these bias we initially ex-
cluded subjects those who considered immunocomprom-
ised. Lastly, in a group with high risk of death, clinical
significance of the statistically significant relationship be-
tween DNI and mortality is limited. In this study, AUC of
DNI was higher than that of WBC or CRP; however, its
absolute value was still low. Future development of pre-
diction models, including DNI through various ap-
proaches, will be helpful for such high-risk patients.
Conclusions
In conclusion, the present study revealed that a greater
increase in DNI levels is significantly associated with se-
verity of disease and high mortality rates in S-AKI pa-
tients treated with CRRT. DNI is an early identifiable
and reliable serologic maker to predict outcomes in pa-
tients with S-AKI requiring CRRT. Patients with high
DNI levels should be cautiously monitored and treat-
ment strategies should be appropriately adapted for their
future needs.
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